Roth Capital Affirms Pieris Pharma (PIRS) at 'Buy' Following Positive PRS-343 Data
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Roth Capital affirms Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) at Buy with a price target of $6 after the company announced that it presented new preclinical data demonstrating in vivo efficacy of its lead 4-1BB (CD137)-based bispecific cancer immunotherapeutic drug candidate, PRS-343.
Analyst Joseph Pantginis commented,
We believe that the results presented today are encouraging and that they build a strong data based foundation for the idea that tumor localized co-stimulatory T cell activation by the bispecific PRS-343 may 1) lead to higher efficacy, and 2) result in reduced systemic toxicity relative to an anti-4-1BB mAb. This foundation, which is the basis for the Phase I trial to be initiated in 1H17, in combination with its manufacturing profile, are critical factors that will weigh in for the potential success of PRS-343, in our belief.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pieris Pharma (PIRS) Receives Milestone Related to GLP Toxicity Study Initiation
- Jefferies Remains Sidelined on Capital One Financial (COF) Following EPS Beat
- UPDATE: Cowen Downgrades Under Armour, Inc. (UA) to Market Perform
Create E-mail Alert Related CategoriesAnalyst Comments, FDA
Related EntitiesRoth Capital, S3
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!